Ninety One SA PTY Ltd Buys 341 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ninety One SA PTY Ltd grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% during the 4th quarter, Holdings Channel reports. The firm owned 4,457 shares of the company’s stock after buying an additional 341 shares during the period. Ninety One SA PTY Ltd’s holdings in IDEXX Laboratories were worth $1,843,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Chicago Partners Investment Group LLC increased its position in IDEXX Laboratories by 16.7% during the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after buying an additional 96 shares during the last quarter. National Pension Service increased its holdings in shares of IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock worth $93,957,000 after acquiring an additional 12,647 shares during the last quarter. Insight Wealth Strategies LLC raised its stake in IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after acquiring an additional 7,041 shares during the period. Larson Financial Group LLC boosted its position in IDEXX Laboratories by 17,238.5% during the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after purchasing an additional 2,241 shares during the period. Finally, Quest Partners LLC increased its holdings in shares of IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after purchasing an additional 2,801 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX opened at $465.03 on Wednesday. The firm has a market cap of $38.08 billion, a P/E ratio of 44.84, a price-to-earnings-growth ratio of 3.64 and a beta of 1.37. The business’s fifty day moving average is $424.92 and its 200-day moving average is $453.54. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.18% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Barclays raised their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Piper Sandler reiterated a “neutral” rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $524.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.